We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of ...

Innovation enables faster adaptation and response to changes, promotes growth, and distinguishes a company from its competitors. The foundation of breakthrough innovations and good science are diverse ...

Job Title Sort ascending Business Location Site Date Posted; Višji strokovnjak za področje vizualne kontrole (m/ž/d) / Senior Visual Inspection Expert (m/f/d) Regulär, Full time Innovative Medicines ...

The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult ...

Key Inclusion Criteria: * 18 years and older at time of signing consent * Patients with primary or secondary wAIHA documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA, ...

Careers at Novartis in Slovenia. At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...

Career Search. Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.. Notice to applicants for US job ...

What is Novartis Managed Access? There are instances where a patient has a serious or life-threatening disease or condition, for which all currently available treatment options have been exhausted and ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

This non-interventional observational study evaluates the real-world effectiveness and safety profile of ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with ...

Inclusion Criteria: - Male or female participants: Pediatric formulation group: ≥ 1 and less than 18 years of age at study entry. Adult formulation group: ≥ 14 and less than 18 years of age and body ...